Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma

Authors: Cristiane A Dalla-Torre, Maisa Yoshimoto, Chung-Hae Lee, Anthony M Joshua, Silvia RC de Toledo, Antônio S Petrilli, Joyce AD Andrade, Susan Chilton-MacNeill, Maria Zielenska, Jeremy A Squire

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Osteosarcoma is a very aggressive tumor with a propensity to metastasize and invade surrounding tissue. Identification of the molecular determinants of invasion and metastatic potential may guide the development of a rational strategy for devising specific therapies that target the pathways leading to osteosarcoma.

Methods

In this study, we used pathway-focused low density expression cDNA arrays to screen for candidate genes related to tumor progression. Expression patterns of the selected genes were validated by real time PCR on osteosarcoma patient tumor samples and correlated with clinical and pathological data.

Results

THBS3, SPARC and SPP1 were identified as genes differentially expressed in osteosarcoma. In particular, THBS3 was expressed at significantly high levels (p = 0.0001) in biopsies from patients with metastasis at diagnosis, which is a predictor of worse overall survival, event-free survival and relapse free survival at diagnosis. After chemotherapy, patients with tumors over-expressing THBS3 have worse relapse free survival. High SPARC expression was found in 51/55 (96.3%) osteosarcoma samples derived from 43 patients, and correlated with the worst event-free survival (p = 0.03) and relapse free survival (p = 0.07). Overexpression of SPP1 was found in 47 of 53 (89%) osteosarcomas correlating with better overall survival, event-free survival and relapse free survival at diagnosis.

Conclusion

In this study three genes were identified with pattern of differential gene expression associated with a phenotypic role in metastasis and invasion. Interestingly all encode for proteins involved in extracellular remodeling suggesting potential roles in osteosarcoma progression. This is the first report on the THBS3 gene working as a stimulator of tumor progression. Higher levels of THBS3 maintain the capacity of angiogenesis. High levels of SPARC are not required for tumor progression but are necessary for tumor growth and maintenance. SPP1 is not necessary for tumor progression in osteosarcoma and may be associated with inflammatory response and bone remodeling, functioning as a good biomarker.
Appendix
Available only for authorised users
Literature
1.
go back to reference Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am. 1997, 44 (4): 973-989. 10.1016/S0031-3955(05)70540-X.CrossRefPubMed Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am. 1997, 44 (4): 973-989. 10.1016/S0031-3955(05)70540-X.CrossRefPubMed
2.
go back to reference Instituto Brasileiro de Geografia e Estatística: Censo Demográfico. http://wwwibgegovbr. 2000 Instituto Brasileiro de Geografia e Estatística: Censo Demográfico. http://​wwwibgegovbr.​ 2000
3.
go back to reference Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Pericles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E: Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006, 24 (7): 1161-1168. 10.1200/JCO.2005.03.5352.CrossRefPubMed Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Pericles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E: Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006, 24 (7): 1161-1168. 10.1200/JCO.2005.03.5352.CrossRefPubMed
4.
go back to reference Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S: A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology. 1996, 53 (3): 221-227.CrossRefPubMed Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S: A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology. 1996, 53 (3): 221-227.CrossRefPubMed
5.
go back to reference Gorlick R, Meyers PA: Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol. 2003, 25 (11): 840-841. 10.1097/00043426-200311000-00003.CrossRefPubMed Gorlick R, Meyers PA: Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol. 2003, 25 (11): 840-841. 10.1097/00043426-200311000-00003.CrossRefPubMed
6.
go back to reference Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002, 2 (8): 563-572. 10.1038/nrc865.CrossRefPubMed Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002, 2 (8): 563-572. 10.1038/nrc865.CrossRefPubMed
7.
go back to reference Cai Z, Chiu JF, He QY: Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics. 2004, 2 (3): 152-166.PubMed Cai Z, Chiu JF, He QY: Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics. 2004, 2 (3): 152-166.PubMed
8.
go back to reference Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995, 270 (5235): 467-470.CrossRefPubMed Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995, 270 (5235): 467-470.CrossRefPubMed
9.
go back to reference Tillmar L, Welsh N: In vitro cultured rat islets express genes that both prevent and promote angiogenesis. Jop. 2004, 5 (2): 81-91.PubMed Tillmar L, Welsh N: In vitro cultured rat islets express genes that both prevent and promote angiogenesis. Jop. 2004, 5 (2): 81-91.PubMed
10.
go back to reference Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, Scavelli C, Nico B, Gernone A, Battelli F, Tabilio A, Guidolin D, Petrucci MT, Ribatti D, Dammacco F: Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003, 102 (9): 3340-3348. 10.1182/blood-2003-04-1338.CrossRefPubMed Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, Scavelli C, Nico B, Gernone A, Battelli F, Tabilio A, Guidolin D, Petrucci MT, Ribatti D, Dammacco F: Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003, 102 (9): 3340-3348. 10.1182/blood-2003-04-1338.CrossRefPubMed
11.
go back to reference Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004, 64 (16): 5617-5623. 10.1158/0008-5472.CAN-03-3927.CrossRefPubMed Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004, 64 (16): 5617-5623. 10.1158/0008-5472.CAN-03-3927.CrossRefPubMed
12.
go back to reference Maxion HK, Kelly KA: Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection. Infect Immun. 2002, 70 (3): 1538-1546. 10.1128/IAI.70.3.1538-1546.2002.CrossRefPubMedPubMedCentral Maxion HK, Kelly KA: Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection. Infect Immun. 2002, 70 (3): 1538-1546. 10.1128/IAI.70.3.1538-1546.2002.CrossRefPubMedPubMedCentral
13.
go back to reference Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L: Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001, 61 (9): 3750-3759.PubMed Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L: Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001, 61 (9): 3750-3759.PubMed
14.
go back to reference Superarray: Superarray Bioscience Corporation: [http://www.superarray.com]. Superarray: Superarray Bioscience Corporation: [http://​www.​superarray.​com].
15.
go back to reference Omnibus NCBIGE: NCBIs Gene Expression Omnibus [http://www.ncbi.nlm.nih.gov/geo/]. Omnibus NCBIGE: NCBIs Gene Expression Omnibus [http://​www.​ncbi.​nlm.​nih.​gov/​geo/​].
16.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
17.
go back to reference Adams J, Lawler J: Extracellular matrix: the thrombospondin family. Curr Biol. 1993, 3 (3): 188-190. 10.1016/0960-9822(93)90270-X.CrossRefPubMed Adams J, Lawler J: Extracellular matrix: the thrombospondin family. Curr Biol. 1993, 3 (3): 188-190. 10.1016/0960-9822(93)90270-X.CrossRefPubMed
19.
go back to reference Frazier WA: Thrombospondins. Curr Opin Cell Biol. 1991, 3 (5): 792-799. 10.1016/0955-0674(91)90052-Z.CrossRefPubMed Frazier WA: Thrombospondins. Curr Opin Cell Biol. 1991, 3 (5): 792-799. 10.1016/0955-0674(91)90052-Z.CrossRefPubMed
20.
go back to reference Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR: Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981, 26 (1 Pt 1): 99-105. 10.1016/0092-8674(81)90037-4.CrossRefPubMed Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR: Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981, 26 (1 Pt 1): 99-105. 10.1016/0092-8674(81)90037-4.CrossRefPubMed
21.
go back to reference Bornstein P, Sage EH: Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002, 14 (5): 608-616. 10.1016/S0955-0674(02)00361-7.CrossRefPubMed Bornstein P, Sage EH: Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002, 14 (5): 608-616. 10.1016/S0955-0674(02)00361-7.CrossRefPubMed
22.
go back to reference Yan Q, Sage EH: SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 1999, 47 (12): 1495-1506.CrossRefPubMed Yan Q, Sage EH: SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 1999, 47 (12): 1495-1506.CrossRefPubMed
23.
go back to reference Bradshaw AD, Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001, 107 (9): 1049-1054.CrossRefPubMedPubMedCentral Bradshaw AD, Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001, 107 (9): 1049-1054.CrossRefPubMedPubMedCentral
24.
go back to reference Denhardt DT, Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998, 30-31: 92-102. 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A.CrossRefPubMed Denhardt DT, Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998, 30-31: 92-102. 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A.CrossRefPubMed
25.
go back to reference O'Regan A, Berman JS: Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000, 81 (6): 373-390. 10.1046/j.1365-2613.2000.00163.x.CrossRefPubMedPubMedCentral O'Regan A, Berman JS: Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000, 81 (6): 373-390. 10.1046/j.1365-2613.2000.00163.x.CrossRefPubMedPubMedCentral
26.
go back to reference Weber GF: The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001, 1552 (2): 61-85.CrossRefPubMed Weber GF: The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001, 1552 (2): 61-85.CrossRefPubMed
27.
28.
go back to reference Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 2004, 91 (11): 1924-1930. 10.1038/sj.bjc.6602213.CrossRefPubMedPubMedCentral Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 2004, 91 (11): 1924-1930. 10.1038/sj.bjc.6602213.CrossRefPubMedPubMedCentral
29.
go back to reference Hankenson KD, Hormuzdi SG, Meganck JA, Bornstein P: Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol. 2005, 25 (13): 5599-5606. 10.1128/MCB.25.13.5599-5606.2005.CrossRefPubMedPubMedCentral Hankenson KD, Hormuzdi SG, Meganck JA, Bornstein P: Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol. 2005, 25 (13): 5599-5606. 10.1128/MCB.25.13.5599-5606.2005.CrossRefPubMedPubMedCentral
30.
go back to reference Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997, 89 (3): 219-227. 10.1093/jnci/89.3.219.CrossRefPubMed Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997, 89 (3): 219-227. 10.1093/jnci/89.3.219.CrossRefPubMed
31.
go back to reference Fontanini G, Boldrini L, Calcinai A, Chine S, Lucchi M, Mussi A, Angeletti CA, Basolo F, Bevilacqua G: Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res. 1999, 5 (1): 155-161.PubMed Fontanini G, Boldrini L, Calcinai A, Chine S, Lucchi M, Mussi A, Angeletti CA, Basolo F, Bevilacqua G: Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res. 1999, 5 (1): 155-161.PubMed
32.
go back to reference Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ, Wolf HK: Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch. 2001, 438 (2): 116-120. 10.1007/s004280000302.CrossRefPubMed Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ, Wolf HK: Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch. 2001, 438 (2): 116-120. 10.1007/s004280000302.CrossRefPubMed
33.
go back to reference Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol. 2001, 159 (1): 223-235.CrossRefPubMedPubMedCentral Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol. 2001, 159 (1): 223-235.CrossRefPubMedPubMedCentral
34.
go back to reference Poon RT, Chung KK, Cheung ST, Lau CP, Tong SW, Leung KL, Yu WC, Tuszynski GP, Fan ST: Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res. 2004, 10 (12 Pt 1): 4150-4157. 10.1158/1078-0432.CCR-03-0435.CrossRefPubMed Poon RT, Chung KK, Cheung ST, Lau CP, Tong SW, Leung KL, Yu WC, Tuszynski GP, Fan ST: Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res. 2004, 10 (12 Pt 1): 4150-4157. 10.1158/1078-0432.CCR-03-0435.CrossRefPubMed
35.
go back to reference Qian X, Tuszynski GP: Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med. 1996, 212 (3): 199-207.CrossRefPubMed Qian X, Tuszynski GP: Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med. 1996, 212 (3): 199-207.CrossRefPubMed
36.
go back to reference Chandrasekaran L, He CZ, Al-Barazi H, Krutzsch HC, Iruela-Arispe ML, Roberts DD: Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell. 2000, 11 (9): 2885-2900.CrossRefPubMedPubMedCentral Chandrasekaran L, He CZ, Al-Barazi H, Krutzsch HC, Iruela-Arispe ML, Roberts DD: Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell. 2000, 11 (9): 2885-2900.CrossRefPubMedPubMedCentral
37.
go back to reference Jundt G, Berghauser KH, Termine JD, Schulz A: Osteonectin--a differentiation marker of bone cells. Cell Tissue Res. 1987, 248 (2): 409-415. 10.1007/BF00218209.CrossRefPubMed Jundt G, Berghauser KH, Termine JD, Schulz A: Osteonectin--a differentiation marker of bone cells. Cell Tissue Res. 1987, 248 (2): 409-415. 10.1007/BF00218209.CrossRefPubMed
38.
go back to reference Sodek J, Zhu B, Huynh MH, Brown TJ, Ringuette M: Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res. 2002, 43 (2-3): 308-319.CrossRefPubMed Sodek J, Zhu B, Huynh MH, Brown TJ, Ringuette M: Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res. 2002, 43 (2-3): 308-319.CrossRefPubMed
39.
go back to reference Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999, 30 (3): 339-344. 10.1016/S0046-8177(99)90014-X.CrossRefPubMed Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999, 30 (3): 339-344. 10.1016/S0046-8177(99)90014-X.CrossRefPubMed
40.
go back to reference Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE: The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res. 2002, 62 (18): 5351-5357.PubMed Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE: The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res. 2002, 62 (18): 5351-5357.PubMed
41.
go back to reference Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M: Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer. 2003, 97 (10): 2412-2419. 10.1002/cncr.11368.CrossRefPubMed Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M: Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer. 2003, 97 (10): 2412-2419. 10.1002/cncr.11368.CrossRefPubMed
42.
go back to reference Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS: SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 1996, 12 (9): 1895-1901.PubMed Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS: SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 1996, 12 (9): 1895-1901.PubMed
43.
go back to reference Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62 (24): 7357-7363.PubMed Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62 (24): 7357-7363.PubMed
44.
go back to reference Bos TJ, Cohn SL, Kleinman HK, Murphy-Ulrich JE, Podhajcer OL, Rempel SA, Rich JN, Rutka JT, Sage EH, Thompson EW: International Hermelin brain tumor symposium on matricellular proteins in normal and cancer cell-matrix interactions. Matrix Biol. 2004, 23 (1): 63-69. 10.1016/j.matbio.2004.01.002.CrossRefPubMed Bos TJ, Cohn SL, Kleinman HK, Murphy-Ulrich JE, Podhajcer OL, Rempel SA, Rich JN, Rutka JT, Sage EH, Thompson EW: International Hermelin brain tumor symposium on matricellular proteins in normal and cancer cell-matrix interactions. Matrix Biol. 2004, 23 (1): 63-69. 10.1016/j.matbio.2004.01.002.CrossRefPubMed
45.
go back to reference Rodan GA, Noda M: Gene expression in osteoblastic cells. Crit Rev Eukaryot Gene Expr. 1991, 1 (2): 85-98.PubMed Rodan GA, Noda M: Gene expression in osteoblastic cells. Crit Rev Eukaryot Gene Expr. 1991, 1 (2): 85-98.PubMed
46.
go back to reference Merry K, Dodds R, Littlewood A, Gowen M: Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci. 1993, 104 ( Pt 4): 1013-1020. Merry K, Dodds R, Littlewood A, Gowen M: Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci. 1993, 104 ( Pt 4): 1013-1020.
47.
go back to reference Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E, Gowen M: Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner Res. 1995, 10 (11): 1666-1680.CrossRefPubMed Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E, Gowen M: Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner Res. 1995, 10 (11): 1666-1680.CrossRefPubMed
48.
go back to reference Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994, 145 (3): 610-623.PubMedPubMedCentral Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994, 145 (3): 610-623.PubMedPubMedCentral
49.
go back to reference Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002, 94 (7): 513-521.CrossRefPubMed Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002, 94 (7): 513-521.CrossRefPubMed
50.
go back to reference Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegard D, Andersson G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis. 2003, 20 (5): 437-444. 10.1023/A:1025419708343.CrossRefPubMed Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegard D, Andersson G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis. 2003, 20 (5): 437-444. 10.1023/A:1025419708343.CrossRefPubMed
51.
go back to reference Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003, 98 (1): 119-127. 10.1002/cncr.11487.CrossRefPubMed Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003, 98 (1): 119-127. 10.1002/cncr.11487.CrossRefPubMed
52.
go back to reference Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 2005, 93 (4): 453-457. 10.1038/sj.bjc.6602715.CrossRefPubMedPubMedCentral Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 2005, 93 (4): 453-457. 10.1038/sj.bjc.6602715.CrossRefPubMedPubMedCentral
53.
go back to reference Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S: The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 2002, 55 (5): 381-385.CrossRefPubMedPubMedCentral Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S: The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 2002, 55 (5): 381-385.CrossRefPubMedPubMedCentral
Metadata
Title
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma
Authors
Cristiane A Dalla-Torre
Maisa Yoshimoto
Chung-Hae Lee
Anthony M Joshua
Silvia RC de Toledo
Antônio S Petrilli
Joyce AD Andrade
Susan Chilton-MacNeill
Maria Zielenska
Jeremy A Squire
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-237

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine